Trials / Completed
CompletedNCT03626662
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 79 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
This is a first-in-human, randomized, double-blind, placebo-controlled, single ascending dose study in subjects with elevated plasma Lipoprotein(a) \[Lp(a)\]. AMG 890 will be evaluated in approximately 80 subjects to assess safety, tolerability, pharmacokinetics and pharmacodynamic effects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMG 890 | Ascending Single Doses of AMG 890 |
| DRUG | Placebo | Calculated volume to match experimental drug. |
Timeline
- Start date
- 2018-07-30
- Primary completion
- 2023-04-18
- Completion
- 2023-04-18
- First posted
- 2018-08-13
- Last updated
- 2026-01-28
- Results posted
- 2026-01-28
Locations
9 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03626662. Inclusion in this directory is not an endorsement.